PMI delivered an outstanding 2025, achieving a fifth consecutive year of positive volume growth driven by a 12.8% increase in smoke-free shipments. Adjusted diluted EPS grew 15% in dollar terms (14.2% currency-neutral) to $7.54, significantly exceeding expectations, while the adjusted operating margin expanded 140 basis points to 40.4%. Smoke-free net revenue reached $17 billion, representing 41.5% of total company revenue, with ZYN shipments growing 36% globally and IQOS volumes increasing 11%. For 2026, the company forecasts organic net revenue growth of 5-7% and adjusted EPS of $8.09-$8.54, despite transitory headwinds from Japanese excise taxes and US inventory dynamics. PMI renewed its medium-term targets (2026-2028), projecting a 9-11% currency-neutral EPS CAGR, and targets a leverage ratio of 2x by 2026.
| Metric | Value | Change |
|---|---|---|
| Adjusted Diluted EPS | $7.54 | +15.0% (Reported) |
| Currency-Neutral Adj. EPS Growth | 14.2% | +14.2% |
| Adjusted Operating Income | $16.4 billion | +11.8% |
| Adjusted Operating Margin | 40.4% | +140 bps (Organic) |
| Smoke-Free Net Revenue | $17 billion | +14.1% (Organic) |
| Smoke-Free Shipments | 179 billion units | +12.8% |
| Total Shipment Volume | N/A | +1.4% |
| ZYN Shipment Growth | 13.6 billion units | +36.0% |
| IQOS Shipment Growth | 155 billion units | +11.0% |
| Operating Cash Flow | $12.2 billion | 0% (Matching 2024) |
PMI's smoke-free transformation has reached a critical scale, now generating 41.5% of total net revenue ($17 billion) and 43% of gross profit. This shift is driving significant margin expansion, with the adjusted operating margin surpassing 40%. The company's multi-category strategy is proving successful, with ZYN (nicotine pouches), IQOS (heated tobacco), and VIVE (e-vapor) all contributing to double-digit smoke-free volume growth. This validates the 'RRP' (Reduced Risk Product) investment thesis and positions PMI to sustain growth even as combustible volumes decline.
The US market represents a massive growth vector, with ZYN shipments growing 37% in 2025 despite supply constraints. Management highlighted that ZYN holds a 61.5% volume share and over 67% value share in the US nicotine pouch category. The pending FDA authorization for 'ZYN Ultra' (higher nicotine strengths and new flavors) and 'IQOS ILUMA' are key catalysts for 2026-2027. Management noted that once these products are approved, they will address current portfolio gaps and drive further premiumization.
PMI is successfully navigating a complex regulatory and tax landscape, specifically in Japan where heat-not-burn excise taxes are set to rise in April and October 2026. Rather than retreating, management submitted price increase applications to offset this headwind. They view the tax changes as 'transitory' and expect the underlying category growth trend to resume in 2027, demonstrating confidence in the price elasticity and brand loyalty of IQOS users.
Capital allocation remains disciplined and shareholder-friendly. With the dividend payout ratio now near the 75% target, PMI announced an 8.9% dividend increase. Simultaneously, the company is aggressively deleveraging, targeting a net debt-to-EBITDA ratio of 2x by year-end 2026. This financial flexibility allows for continued heavy investment in smoke-free commercialization and innovation while returning cash to shareholders.
The 2026 guidance includes specific 'transitory headwinds' that could create volatility. In Japan, excise tax increases of 50-100 yen per pack (representing 10-20% of retail prices) are expected to dampen volume growth and shipment timing in the first half of the year. Management warned of 'shipment volatility' around the tax implementation dates in April and October, which could lead to uneven quarterly performance.
The US regulatory environment remains a significant uncertainty. While management expressed optimism about FDA authorizations for ZYN Ultra and IQOS ILUMA, they admitted they have 'not had a great track record of forecasting FDA' timing. Delays in these approvals would prevent PMI from closing portfolio gaps with competitors, particularly in the higher nicotine strength segments that are currently driving category growth.
ZYN inventory dynamics in the US are creating a disconnect between shipment and consumption data. Management identified approximately 25 million cans of surplus inventory in the downstream supply chain that needs to normalize, likely in Q1 2026. This destocking could artificially suppress shipment growth figures in the near term, even if underlying consumer demand remains robust.
Competitive intensity is rising in key markets. In Japan, new product launches from rivals have stepped up, and in the US, the nicotine pouch category is seeing elevated promotional activity. While PMI maintains premium pricing, the need to increase investment in brand building and promotions to defend share could pressure margins if the competitive environment escalates further than anticipated.
Overall: Management exhibited a high degree of confidence and satisfaction throughout the call, frequently characterizing 2025 as 'outstanding' and highlighting the company's 'best-in-class' growth profile. While acknowledging specific headwinds for 2026, particularly regarding Japanese tax increases and US regulatory timing, the tone remained bullish on the long-term structural shift toward smoke-free products. Executives spoke with authority about market share gains and the financial capacity to drive future growth.
Confidence: HIGH - Management consistently exceeded guidance in 2025 and proactively renewed ambitious three-year targets for 2026-2028. Their language was definitive regarding the 'structural movement' of the category and the company's ability to navigate 'transitory' headwinds through pricing and innovation.
5% to 7%
7% to 9%
7.5% to 9.5%
$8.09 to $8.54
High single digit to low teens
~3%
6% to 8%
9% to 11%
Hedging & Uncertainty: Management employed hedging primarily regarding the timing of external factors, specifically FDA decisions and the precise impact of Japanese tax changes. Phrases like 'subject to the timing of launch,' 'pending FDA action,' and 'shipment volatility... is possible' were used to qualify 2026 guidance. However, hedging was notably absent regarding the long-term structural growth of the smoke-free category, where language was assertive ('lasting structural movement'). They used temporal qualifiers to soften 2026 headwinds, labeling them as 'transitory' or 'atypical' to distinguish them from the long-term trajectory.
The shift of adult smokers to better alternatives is a lasting structural movement - Jacek Olczak, Group CEO
We are today renewing these growth targets for the next three years, further validating our best-in-class growth profile - Jacek Olczak, Group CEO
2026 an atypical year... The level of the increase makes this a headwind for the category - Jacek Olczak, Group CEO
We have a comprehensive commercial program plan for 2026... commercial activities, including promotions, were unusually low in the 2025 - Emmanuel Babeau, CFO
I don't think the algorithm... is heavily or material dependent on the IQOS... in the US - Jacek Olczak, Group CEO
Analyst Sentiment: Analysts were highly engaged, focusing heavily on the sustainability of growth rates, the specific mechanics of the Japanese tax headwind, and the timing of US FDA approvals. There was a clear interest in understanding how the 'algorithm' for the new medium-term targets (2026-2028) accounts for these variables.
Management Responses: Management was transparent about the mathematical drivers of their guidance but remained guarded on specific innovation details for competitive reasons. They deflected questions about precise elasticities in Japan and specific FDA timelines, preferring to emphasize the robustness of the overall portfolio and the 'structural' nature of the demand.
Discussion on the re-acceleration of smoke-free volume growth post-2026, driven by the normalization of Japanese taxes and the potential launch of IQOS and ZYN Ultra in the US.
Detailed scrutiny of the Japanese market, specifically the impact of the April and October excise tax increases on pricing and volume.
Inquiries regarding the 'asymmetry' of the US ZYN portfolio versus competitors, specifically the lack of higher nicotine strengths and flavors pending FDA action.
Questions about the 2026 guidance step-down from 2025 levels, with management clarifying the impact of the 'high base' comparison and inventory normalization.
Philip Morris International has successfully transitioned into a smoke-free growth engine, with 41.5% of revenue now derived from reduced-risk products. The company's execution in 2025 was exceptional, delivering double-digit EPS growth and significant margin expansion. While 2026 faces transitory headwinds from Japanese tax hikes and US inventory dynamics, the underlying fundamentals remain robust. The renewal of medium-term targets (9-11% EPS CAGR) signals management's confidence in the durability of this growth. The pending US launches of ZYN Ultra and IQOS ILUMA represent significant upside catalysts that are not yet fully priced into the current algorithm. PMI remains a best-in-class compounder with a shareholder-friendly capital allocation policy.
Upcoming excise tax increases in Japan (April and October 2026) are expected to create volatility and dampen category growth by 10-20% on price points. Additionally, the US regulatory environment remains 'dynamic and uncertain,' pending FDA authorizations for new products.
Management noted that the shift to smoke-free products is a 'lasting structural movement' rather than a temporary trend. In Japan, despite inflationary pressures, heat-not-burn consumers have shown higher price resilience than cigarette smokers.
The 2026 guidance includes a $0.28 benefit from currency translation, driven by the absence of non-recurring transactional losses experienced in 2025 and favorable hedging positions, particularly against the Euro.